This episode breaks down what MGUS truly represents and why it’s so often misunderstood. It explains how a small, silent monoclonal protein fits into the spectrum of plasma cell disorders, why most people with MGUS feel completely well, and what actually drives the risk of progression to myeloma or related conditions. The discussion walks through the essential diagnostic labs, the Mayo Clinic risk model, and how to distinguish harmless MGUS from cases where the protein begins to damage organs. It also explores smoldering myeloma, MGRS, and AL amyloidosis, helping listeners understand when a quiet lab finding becomes clinically significant.

Source:

Monoclonal Gammopathy of Undetermined Significance (Review) from NEJM